PHAT gets bigger: Phathom Pharma prices upsized IPO at $19 midpoint

Phathom Pharmaceuticals, a Phase 3 biotech developing novel therapies for gastrointestinal diseases, raised $182 million by offering 9.6 million shares at $19, the midpoint of the $18 to $20 range. The company upsized its offering by 21%. Phathom Pharmaceuticals plans to list on the Nasdaq under the symbol PHAT. Goldman Sachs, Jefferies and Evercore ISI acted as lead managers on the deal.

Relevant Profile: PHAT

https://www.renaissancecapital.com/IPO-Center/News/65619/PHAT-IPO-gets-bigger-Phathom-Pharmaceuticals-prices-upsized-IPO-at-$19-midp